Highlights
This is my archive
IOB’s first spinout: RhyGaze AG
RhyGaze, an innovative spinout from the Basel based IOB, is proud to announce that it has successfully raised a CHF 10 million seed round. The round was co-led by Dutch venture capital firm BioGeneration Ventures (BGV) and the Novartis Venture Fund (NVF). RhyGaze AG is pioneering a transformative approach with…
IOB’s winter highlights 2024
Postdoctoral fellow Arjun Bharioke became Assistant Professor at the Medical University of South Carolina (MUSC, Charleston, USA). His new lab combines optical methods to interrogate circuits with computational modelling and simulations, to build an understanding of how cortical circuits form, respond to changes, and generate cognitive functions. Warm congratulations to Veronica Moreno Juan…
Spotlight on vision science: IOB featured in Novartis Live N°19
We are delighted to be featured in the latest issue of Novartis Live magazine. The beautifully designed brochure highlights IOB’s work and mission, from groundbreaking work in optogenetics and gene therapy to our growing international team of researchers and to patient impact. We are thrilled and deeply grateful to see our…
IOB’s first spinout RhyGaze receives major funding
RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who…
Better & more precise diagnostics of genetic diseases
Some variants in human genes have no consequences – they are benign, while others cause disease – they are pathogenic and are called mutations. A team led by Carlo Rivolta, Head of our Ophthalmic Genetics Group, in collaboration with the teams of Andrea Superti-Furga (Lausanne University Hospital) and David Cooper…